Beverly Moy
Overview
Explore the profile of Beverly Moy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
4935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):27.
PMID: 40069204
Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat...
2.
Sood R, Niemierko A, Ryan L, Spring L, Moy B, Bardia A, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39869305
Background: Race/ethnicity may affect outcomes in metastatic breast cancer (MBC) due to biological and social determinants. We evaluated the impact of race/ethnicity on clinical, socioeconomic, and genomic characteristics, clinical trial...
3.
Spring L, Scarpetti L, Medford A, Niemierko A, Comander A, Mulvey T, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):2.
PMID: 39774684
Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib...
4.
Abelman R, Wu B, Barnes H, Medford A, Norden B, Putur A, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39745368
Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of ADC resistance mechanisms and potential impact on...
5.
Medford A, Moy B
JCO Oncol Pract
. 2024 Nov;
20(11):1515-1522.
PMID: 39531843
Molecular prognostic and diagnostic tools allow for targeted cancer surveillance, prognostication, and treatment, and these assays have the potential to improve the lives of patients and their relatives. The impact...
6.
May F, Brodney S, Tuan J, Syngal S, Chan A, Glenn B, et al.
Contemp Clin Trials
. 2024 Jul;
145():107639.
PMID: 39068985
Introduction: Colorectal cancer (CRC) screening utilization is low among low-income, uninsured, and minority populations that receive care in community health centers (CHCs). There is a need for evidence-based interventions to...
7.
Bardia A, Sun S, Thimmiah N, Coates J, Wu B, Abelman R, et al.
Clin Cancer Res
. 2024 May;
30(14):2917-2924.
PMID: 38709212
Purpose: The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor (TOP1i) SN-38, coupled to a monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP-2). Poly(ADP-ribose) polymerase...
8.
Sedrak M, Sun C, Bae M, Freedman R, Magnuson A, OConnor T, et al.
J Cancer Surviv
. 2024 Apr;
18(4):1131-1143.
PMID: 38678525
Purpose: This study aimed to assess whether physical functional decline in older women with early-stage breast cancer is driven by cancer, chemotherapy, or a combination of both. Methods: We prospectively...
9.
Warner E, Moy B
NEJM Evid
. 2024 Feb;
1(12):EVIDe2200259.
PMID: 38319831
The use of adjuvant bone-modifying agents to reduce risk of recurrence in patients with early-stage breast cancer has not been widely embraced because of conflicting data and small absolute benefits....
10.
Al Sukhun S, Temin S, Barrios C, Antone N, Guerra Y, Chavez-MacGregor M, et al.
JCO Glob Oncol
. 2024 Jan;
10:e2300285.
PMID: 38206277
Purpose: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting-guideline recommended treatment is unavailable. Methods: A multidisciplinary, multinational...